Quality of life and treatment related toxicity in 335 patients with locally advanced cervical carcinoma treated by two chemoradiation regimens

Journal of B.U.ON.

Volumn 12, Issue 3, 2007, Pages 389-394

  Nagy, Viorica ^a,b   Todor, N ^a   Coza, O ^a,b   Ordeanu, C ^a   Ghilezan, N ^a,b  

^a THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Acute toxicity; Cervical cancer; Chemoradiotherapy; Quality of life

Indexed keywords

CISPLATIN; HEMOGLOBIN; ONDANSETRON;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PAIN; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; EMOTIONAL STRESS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GASTROINTESTINAL TOXICITY; HEALTH STATUS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYSTERECTOMY; LEUKOCYTE DISORDER; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE DISORDER; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; QUALITY OF LIFE; RADIATION-SENSITIZING AGENTS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 35248814231     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Suteu O, Ghilezan N, Todor N, Scortan E. Uterine cervix cancer epidemiology in Romania 1959-1999. Radioterapie & Oncologie Medicala 2001; 7: 40-51 (in Romanian with Engl abstr).
2. Whitney CW, Sause W, Bundy BN. Arandomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative paraaortic lymph nodes. A Gynecologic Oncology Group and Southwest Group study. J Clin Oncol 1999; 17: 1339-1348.
3. Morris M, Eifel PJ, Lu J. Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340: 1137-1143.
4. Rose PG, Bundy BN, Watkins EB. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144-1153.
5. Peters WA, Liu PY, Barrett RJ. Cisplatin and 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high-risk early-stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: report of a phase III intergroup study. J Clin Oncol 2000; 8: 1606-1613.
6. Keys HM, Bundy BN, Stehman FB. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340: 1154-1161.
7. Eifel PJ. Problems with the clinical staging of carcinoma of the cervix. Semin Oncol 1994; 4: 1-5.
8. Aaronson NK, Ahmedzai S, Bergman B et al. The EORTC QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
9. NCI: Common Toxicity Criteria, Version 2.0. In: Cancer Therapy Evaluation Program, National Cancer Institute, June 1, 1999.
10. Chapt TL (Ed). Introductory Biostatistics. John Wiley & Sons, New York, 2003.
11. Rosner B (Ed). Fundamentals of Biostatistics (5th edn). Duxbury, USA, 2000.
12. Green J, Kirwan JM, Tierney JF, Sysmonds P. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systemic review and metaanalysis. Lancet 2001; 358: 781-786.
13. Nagy V. Changes in natural history of cervical cancer through concomitant radio-chemotherapy. Radioterapie & Oncologie Medicala 2003; 9: 21-26 (in Romanian with Engl abstr).
14. Gonzalez AD, Perez LC, Graniel CL. Pathologic response and toxicity assessment of chemotherapy with cispaltin versus cisplatin plus gemcitabine in cervical cancer: a randomized phase II study. Int J Radiat Oncol Biol Phys 2005; 61: 817-823.
15. Monk BJ, Huang HQ, Cella D, Long HJ. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: 4617-4625.